Uli Hacksell is the Chairman of the Board at Medivir AB, bringing extensive experience from the pharmaceutical industry. He previously served as CEO of ACADIA Pharmaceuticals for 15 years, guiding the company through significant growth. He holds a Ph. D. in medicinal chemistry from Uppsala University and is an expert in drug development.
He successfully led ACADIA Pharmaceuticals in developing NUPLAZID, the first drug approved for psychosis in Parkinsons disease.
Uli Hacksell
Styrelseordförande at Medivir AB
Tampa, Florida, United States
Overview
Topics They Care About
Drug Development
His career has been dedicated to advancing new medicines from research to market, particularly in challenging therapeutic areas.
CNS Disorders
Possesses deep expertise in Central Nervous System disorders, having led the development of a breakthrough drug for Parkinson's disease psychosis at ACADIA Pharmaceuticals.
Biotech Leadership
As a long-time CEO and current Chairman, he focuses on corporate strategy, financing, and steering biotech companies towards clinical and commercial success.
Media Appearances
Uli has no verified media appearances
Work History
Styrelseordförande at Medivir AB
Education
Uli has no verified education history
More Information
Social Presence :
Prographics :
Exp : N/A
Location : Tampa, Florida, United States
Job Level : N/A
Designation : Styrelseordförande at Medivir AB
